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Abstract
Background/Aims: Chronic inflammation contributes to cartilage degeneration during the 
progression of osteoarthritis (OA). Adipose tissue-derived mesenchymal stem cells (AD-
MSC) show great potential to treat inflammatory and degradative processes in OA and have 
demonstrated paracrine effects in chondrocytes. In the present work, we have isolated and 
characterized the extracellular vesicles from human AD-MSC to investigate their role in the 
chondroprotective actions of these cells. Methods: AD-MSC were isolated by collagenase 
treatment from adipose tissue from healthy individuals subjected to abdominal lipectomy 
surgery. Microvesicles and exosomes were obtained from conditioned medium by filtration 
and differential centrifugation. Chondrocytes from OA patients were used in primary culture 
and stimulated with 10 ng/ml interleukin(IL)-1β in the presence or absence of AD-MSC 
microvesicles, exosomes or conditioned medium. Protein expression was investigated by 
ELISA and immunofluorescence, transcription factor-DNA binding by ELISA, gene expression 
by real-time PCR, prostaglandin E2 (PGE2) by radioimmunoassay, and matrix metalloproteinase 
(MMP) activity and nitric oxide (NO) production by fluorometry. Results: In OA chondrocytes 
stimulated with IL-1β, microvesicles and exosomes reduced the production of inflammatory 
mediators tumor necrosis factor-α, IL-6, PGE2 and NO. The downregulation of cyclooxygenase-2 
and microsomal prostaglandin E synthase-1 would lead to the decreased PGE2 production 
while the effect on NO could depend on the reduction of inducible nitric oxide synthase 
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expression. Treatment of OA chondrocytes with extracellular vesicles also decreased the release 
of MMP activity and MMP-13 expression whereas the production of the anti-inflammatory 
cytokine IL-10 and the expression of collagen II were significantly enhanced. The reduction 
of inflammatory and catabolic mediators could be the consequence of a lower activation of 
nuclear factor-κB and activator protein-1. The upregulation of annexin A1 specially in MV may 
contribute to the anti-inflammatory and chondroprotective effects of AD-MSC. Conclusions: 
Our data support the interest of AD-MSC extracellular vesicles to develop new therapeutic 
approaches in joint conditions.
Introduction
Chronic production of inflammatory mediators has important implications for 
chondrocyte metabolism in joint diseases. Pro-inflammatory cytokines contribute to 
alterations in osteoarthritis (OA) joint metabolism through the production of inflammatory 
mediators and catabolic enzymes capable of destroying cartilage matrix [1-3], and the 
downregulation of anti-inflammatory and anabolic genes [4]. OA remains a leading cause 
of disability in the elderly without an effective treatment. At present, the treatment of OA 
is targeted to control symptoms although innovative therapeutic approaches such as joint 
injection of mesenchymal stem cells (MSC) and differentiation into chondrocytes using 
appropriate scaffolds to regenerate cartilage are being investigated [5].
MSC have opened a new avenue for treating tissue injury and inflammation. In particular, 
adipose tissue-derived mesenchymal stem cells (AD-MSC) show great therapeutic potential 
and have demonstrated protective properties in animal models of OA. Therefore, injection 
of these cells into the knee joint is able to reduce inflammation and cartilage degradation 
induced by collagenase in mice [6] or by anterior cruciate ligament transection in rabbits [7].
MSC cell therapy has demonstrated beneficial effects despite short-lived survival 
of the delivered cells suggesting that secreted factors may be the active components. 
There is evidence that MSC secrete into their microenvironment a number of cytokines 
and growth factors that regulate intracellular signaling pathways in neighboring cells, 
promote angiogenesis and recruitment of stem/progenitor cells, or exert trophic and 
immunomodulatory effects (reviewed in [8]). As a result, treatment of OA chondrocytes 
or synovial cells with conditioned medium (CM) from bone marrow MSC or AD-MSC in an 
inflammatory environment can inhibit the production of inflammatory and catabolic agents 
[9, 10].
It is now recognized that MSC release extracellular vesicles (EV) as vehicles for 
intercellular communication. In particular, microvesicles (MV) are a heterogeneous 
population of spherical structures with a diameter of 100–1000 nm which are released 
by ectocytosis of the plasma membrane [11] while exosomes (EX) are membrane vesicles 
with a diameter of 40–100 nm, formed by endocytosis, stored intracellularly and secreted 
when endosomal structures fuse with the plasma membrane [12]. In recent years, there 
has been significant interest in MSC EV as mediators of regenerative responses with 
potential therapeutic applications in cardiovascular diseases [13], rheumatic diseases [14], 
fracture healing [15], neurodegeneration [16] or immunomodulation [17]. In relation with 
cartilage metabolism, it has been shown recently that EX from HuES9 human embryonic 
stem cells are able to repair osteochondral defects in rats [18] and EX from miR-140-5p-
overexpressing human synovial MSC prevent the development of OA-like changes after 
surgical destabilization of the rat knee [19].
We have previously reported the anti-inflammatory and protective properties of CM 
from AD-MSC in OA chondrocytes [20, 21]. Despite these studies, the possible contribution 
of EV to the observed effects is not known. To address this issue, we have assessed how MV 
and EX isolated from this CM could affect the metabolism of OA chondrocytes by modulating 
inflammatory and degradative pathways relevant in joint destruction.
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Materials and Methods
Adipose tissue-derived mesenchymal stem cells
AD-MSC were obtained from the adipose tissue of 10 non-obese donors (4 men and 7 women, aged 
53.8±7.4 years, mean±SEM) who had undergone abdominoplasty. The experimental design was approved 
by the Institutional Ethical Committees (University of Valencia and La Fe Polytechnic University Hospital, 
Valencia, Spain). Samples were obtained from donors after they provided informed consent according to the 
Helsinki Declaration of 1975, as revised in 2013.
Adipose tissue samples were washed with phosphate-buffered saline (PBS), minced, digested at 37ºC 
for 1 h with 2% of type I collagenase (Gibco, Life Technologies, Madrid, Spain) and filtered through a 100 μm 
cell strainer (BD Biosciences, Bedford, MA, USA). Then, cells were washed with DMEM/HAM F12 (Sigma-
Aldrich, St. Louis, MO, USA) containing penicillin and streptomycin (1%), seeded onto tissue culture flasks 
(1–2×106 cells/ml) in DMEM/HAM F12 medium with penicillin and streptomycin (1%) supplemented with 
15% EV-free human serum, and incubated at 37ºC in a 5% CO
2
 atmosphere. Human serum was obtained from 
whole-blood donations of AB-blood-group-typed donors according to the criteria of Valencia Transfusion 
Centre. To eliminate the EV fraction, serum was centrifuged during 18 h at 120, 000×g and 4ºC using a SW-
28 swinging-bucket rotor (Beckman Coulter, Brea, CA, USA). At 24 h, when cells reached semiconfluence, 
culture plates were washed and the AD-MSC phenotype confirmed by flow cytometry (Flow Cytometer II, BD 
Biosciences, San Jose, CA, USA) using specific antibodies: anti-CD105-PE, antiCD90PerCP-eFluo 710, anti-
CD34APC (eBioscience, Inc., San Diego, CA, USA), and anti-CD45-PE (BD Pharmingen™, BD Biosciences). 
Cellular viability was determined with propidium iodide.
Immortalized Human Keratinocytes (HaCaT) cell line was kindly provided by Prof. Norbert E. Fusenig 
(German Cancer Research Institute, Heidelberg, Germany). Cells were cultured in DMEM/HAM F12 with 
penicillin and streptomycin (1%) supplemented with 15% EV-free human serum, and incubated at 37ºC in 
a 5% CO
2
 atmosphere.
CM was collected from AD-MSC and HaCaT culture cells at passage 0 every 48 h of culture. It was 
pooled, centrifuged, and stored in sterile conditions at −80º C prior to further use.
Isolation of EV
EV were obtained from the CM of AD-MSC and HaCaT cells using a filtration/centrifugation-based 
protocol. Cellular debris was eliminated by pelleting with centrifugation at 300×g for 10 min at 4°C. EV 
were then collected from the supernatant through differential centrifugation steps. Briefly, CM was filtered 
through 800 nm filter (Merck, Darmstadt, Germany) and centrifuged at 12, 200×g for 20 min at 4°C to pellet 
MV. Then, supernatants were filtered through 200 nm filter (Merck, Darmstadt, Germany) and centrifuged 
at 100, 000×g for 90 min at 4°C. The resulting pellets containing EX were washed once with sterile PBS, 
resuspended in 15 µl of PBS and stored at -80ºC until use.
Tunable resistive pulse sensing (TRPS)
EV preparations were analyzed by TRPS using a qNano instrument (IZON Sciences Ltd., Oxford, UK) 
[22]. NP100, and NP300 nanopore membranes were used to measure the samples of EX and MV, respectively. 
At least 500 events/sample were counted. Calibration was performed using calibration beads SKP200 and 
SKP400, provided by the manufacturer.
Transmission electron microscopy (TEM)
EV preparation for TEM was performed by the Microscopy Service (SCSIE, University of Valencia). 
Briefly, LR-white resin inclusion was performed fixing EV samples with Karnovsky fixative, inclusion in agar, 
followed by water washing and dehydration in 30% EtOH, 50% EtOH, 70% EtOH and 96% EtOH. Finally, 
samples were sequentially incubated for 2 h in 33% LR-white resin in 96% EtOH, 66% LR-white resin in 
96% EtOH, 66% LR-white resin in 100% EtOH and 100% LR-white resin in 100% EtOH. Samples were 
filtered in resin and polymerized at 60ºC for 48 h. Then, ultrathin slices (60 nm) were made with a diamond 
blade (DIATOME, Hartfield, USA) in eyelet grilles in a UC6 Ultracut (Leica, Wetzlar, Germany) and stained 
with uranyl acetate 2% for 25 min and lead citrate 3% for another 12 min prior to visualization in Jeol-1010 
(JEOL Ltd. Tokyo, Japan) at 60 kV. Images were acquired with a digital camera MegaView III with Olympus 
Image Analysis Software (Olympus, Tokyo, Japan).
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For gold-immunostaining, mouse anti-human CD63 monoclonal and goat anti-mouse IgG H&L (10 nm 
Gold) polyclonal antibodies from Abcam (Cambridge, MA, USA) were used. EV were fixed with Karnovsky’s 
fixative and then processed in resin as described above. Grids containing the samples were blocked with 
PBS/0.8% bovine serum albumin (BSA)/0.1% gelatin, and 2 μl of primary antibody in PBS/0.5% BSA were 
added. Grids were then washed with PBS/0.5% BSA, incubated with the gold-labeled secondary antibody 
in PBS/0.5% BSA for 30 min, and then washed in 100 μl drops of PBS/0.5% BSA. Control grids incubated 
with only secondary antibodies were also used. The grids were stained with 2% uranyl acetate and then 
viewed for TEM using a Jeol JEM1010 microscope at 60 kV and images were acquired with a digital camera 
MegaView III with Olympus Image Analysis Software.
Flow Cytometry
Annexin V positive MV were determined with the FITC Annexin V Detection Kit I (BD Biosciences). 
Immediately before incubation, antibody was ultracentrifuged and washed in 0.2 µm filtered-PBS to avoid 
noise, and all solutions were previously filtered. For labeling, EV were diluted down to 500, 000 particles/
ml in labeling buffer with FITC-conjugated annexin V  and incubated at room temperature for 1h in dark. 
After labeling, EV were twice washed and recovered in filtered PBS. EV were then analyzed at a flow rate 
on a LSR Fortessa X-20 flow cytometer (BD Biosciences) and data registered with the software DIVA 8.0 
processed with the software FlowJo (FlowJo LLC, Ashland, OR, USA).  The gating window for counting EV 
and discriminating against background noise was set using forward and side scatter plots for Megamix-Plus 
FSC fluorescent beads (BioCytex, Marseille, France) of diameters 100 nm, 300 nm, 500 nm and 900 nm, 
and FITC fluorescent positivity established as compared to unlabeled EV and EV-free annexin V and FITC-
antibody solutions.
OA chondrocytes
Knee specimens were obtained from patients diagnosed with advanced OA (27 women and 14 men, 
aged 65.6±12.0 years, mean±SEM) who had undergone total joint replacement. The experimental design was 
approved by the Institutional Ethical Committees as indicated above. Cartilage was dissected from the femoral 
condyles and tibial plateau of the knee joint and diced into small pieces. Human articular chondrocytes were 
isolated by sequential enzymatic digestion: 1 h with 0.1 mg/ml hyaluronidase (Sigma-Aldrich) followed by 
12–15 h with 2 mg/ml type IA collagenase (Sigma-Aldrich) in DMEM/HAM F12 containing penicillin and 
streptomycin (1%) at 37ºC in 5% CO
2
 atmosphere. The digested tissue was filtered through a 70 μm nylon 
mesh (BD Biosciences), washed, and centrifuged. Cell viability was greater than 95% according to the Trypan 
blue exclusion test. All experiments were performed with chondrocyte primary cultures at semiconfluence 
(270×103 cells/well in 6-well plates or 1.5×106 cells in 3.5 cm plates). Chondrocytes were maintained with 
5% CO
2
 at 37ºC in DMEM/HAM F12 containing penicillin and streptomycin (1%), supplemented with 10% 
fetal bovine serum (Sigma-Aldrich).
To perform the experiments, chondrocytes and explants were incubated for different times in DMEM/
HAM F12 containing penicillin and streptomycin (1%) supplemented with 15% EV-free human serum and 
stimulated with interleukin(IL)-1β (10 ng/ml) in the presence or absence of AD-MSC- or HaCaT MV (3.6x107 
particles/ml), EX (7.2x107 particles/ml) or CM (0.4 ml for 24-well plates, 1 ml for 6-well plates or 1.5 ml for 
3.5 cm plates).
For explant cultures, full-thickness pieces of cartilage were removed from the femoral condyles. Slices 
measuring ∼2 mm in width × 2 mm in length were dissected from the tissue. Explants were transferred to 
24-well plates (10 explants/well) containing DMEM/HAM F12 medium supplemented with penicillin and 
streptomycin (1%), and 10% fetal bovine serum, and they were incubated in a humidified 5% CO
2
 incubator 
at 37°C for 2 days before assays to allow them to stabilize.
MTT Assay
The mitochondrial dependent reduction of 3-(4, 5-dimethylthiazol-2-yl)-2, 5 diphenyltetrazolium 
bromide (MTT) to formazan was assayed in OA chondrocytes stimulated with IL-1β (10 ng/ml) and treated 
with MV (3.6x107 particles/ml), EX (7.2x107 particles/ml) or CM (0.4 ml) in 24-well plates for 24 h. Cells 
were then incubated with MTT (200 μg/ml) for 2 h. Medium was removed and cells were solubilized in 
dimethyl sulfoxide (100 μl) to quantitate formazan at 550 nm using a Victor3 microplate reader (PerkinElmer 
España, Madrid, Spain).
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Proteomic analysis of EV by mass spectrometry
Proteomic characterization of EV samples was performed by the Proteomics Service of the Servei 
Central de Suport a la Investigació Experimental (Universitat de València). Briefly, 10 µg per EV sample 
were digested with Triton X-100 and separated by 1-D SDS PAGE. Peptides were generated by a trypsin 
digestion, extracted, and examined by LC using a NanoLC Ultra 1-D plus Exsigent (Eksigent Technologies, 
Dublin, CA, USA) which was directly connected to an AB SCIEX TripleTOF 5600 mass spectrometer (AB 
SCIEX, Framingham, MA, USA) in direct injection mode. After LC-MS/MS, the SCIEX.wiff data-files were 
processed using ProteinPilot v5.0 search engine (AB SCIEX). The resulting ProteinPilot group file was 
loaded into PeakView® (v2.1, AB SCIEX) and peaks were extracted with a peptide confidence threshold 
of 99% confidence (Unused Score ≥ 1.3) and a false discovery rate (FDR) lower than 1%. For this, the MS/
MS spectra of the assigned peptides were extracted by ProteinPilot, and only the proteins that fulfilled the 
following criteria were validated: (1) peptide mass tolerance lower than 10 ppm, (2) 99% of confidence 
level in peptide identification, and (3) complete b/y ions series found in the MS/MS spectrum. The identified 
proteins were quantified using PeakView® from normalized label-free quantification (LFQ) intensity data. 
The quantitative data obtained by PeakView® were analyzed using MarkerView® (v1.2, AB SCIEX). First, 
areas were normalized by total areas summa. Principal Component Analysis (PCA) was performed to evaluate 
the discriminative ability of proteins in different EV fractions. Bioinformatics analysis of identified and 
validated SP-proteins was manually performed using the comprehensive bioinformatics tool for functional 
annotation UniProt KB database (www.uniprot.org) in combination with PANTHER (www.pantherdb.org) 
and FunRich (http://www.funrich.org). Data are available via ProteomeXchange with identifier PXD009077 
and 10.6019/PXD009077.
ELISA
Chondrocytes were stimulated with IL-1β (10 ng/ml) in presence or absence of MV (3.6x107 particles/
ml), EX (7.2x107 particles/ml) or CM (1 ml) for 24 h, or 1h for transcription factors detection. Supernatants 
were centrifuged and stored at -80ºC until analysis. Tumor necrosis factor-α (TNFα), IL-6, and IL-10 were 
measured by enzyme-linked immunosorbent assay (ELISA) kits from eBioscience (San Diego, CA, USA) 
with a sensitivity of 4.0 pg/ml for TNFα and IL-6, and 2.0 pg/ml for IL-10. Nuclear factor-κB (NF-κB) and 
activator protein-1 (AP-1) binding to DNA was quantified by ELISA in nuclear extracts using the Nuclear 
Extract Kit Active Motif for nuclei extraction followed by TransAM p65 NF-κB and TransAM c-Jun Activation 
Assay kits (Active Motif Europe, Rixensart, Belgium), according to the manufacturer’s recommendations.
Determination of MMP activity, NO and PGE2
Chondrocytes were stimulated as indicated above and supernatants were harvested and centrifuged. 
For matrix metalloproteinase (MMP) activity determination, supernatants were incubated with 
p-aminophenylmercuric acetate for 12 h at 37ºC to activate MMPs. Then, supernatants were transferred to a 
96-well plate. After addition of the 5- FAM peptide substrate (AnaSpec Inc., San Jose, CA, USA), fluorescence 
was measured at 490 nm (excitation)/520 nm (emission) in a Victor3 microplate reader (PerkinElmer 
España). Prostaglandin E
2
 (PGE
2
) was quantitated in supernatants by radioimmunoassay [23] and nitric 
oxide (NO) production was assessed by fluorometric determination of nitrite levels [24] using a Victor3 
microplate reader (PerkinElmer España).
Real-time PCR
Total RNA was extracted from OA chondrocytes using the TriPure reagent (Roche Life Science, 
Barcelona, Spain) according to the manufacturer’s instructions. Reverse transcription was accomplished 
on 1 μg of total RNA using random primers and Transcriptor First Strand cDNA Synthesis Kit (Roche Life 
Science). PCR assays were performed in duplicate on an iCycler Real-Time PCR Detection System using SYBR 
Green PCR Master Mix (Bio-Rad Laboratories, Richmond, CA, USA). Primers were synthesized by Eurofins 
MWG Operon (Ebersberg, Germany) [20]. For each sample, differences in threshold cycle (ΔCt) values were 
calculated by correcting the Ct of the gene of interest to the Ct of the reference gene β-actin. Relative gene 
expression was expressed as 2-ΔΔCt with respect to non-stimulated cells.
Immunofluorescence
Chondrocytes were seeded at 20x103 cells/well in Lab-tek chambers (Thermo Scientific, Rochester, 
NY, USA) and stimulated with IL-1β (10 ng/ml) in the presence or absence of MV (3.6x107 particles/ml), EX 
(7.2x107 particles/ml) or CM (0.2 ml) for 24h (annexin A1) or 5 days (collagen II). Cells were fixed with 4% 
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formaldehyde in PBS for 30 min at 4ºC, blocked with 1% BSA in PBS for 20 min at room temperature and 
incubated with rabbit anti-human type II collagen polyclonal antibody (Chemicon/Millipore, Schwalbach, 
Germany) or MaxPab rabbit anti-annexin A1 polyclonal antibody (Abnova, New Taipei, Taiwan) followed by 
incubation with goat anti-rabbit IgG-FITC (R&D Biosystems, Abingdon, UK). Slides were mounted in Prolong 
Gold antifade reagent with DAPI (Molecular Probes, Invitrogen, Life Technologies) and examined under 
a confocal microscope (Olympus FV1000, Tokyo, Japan). Collagen II- or annexin A1-positive cells were 
observed in 6 microscopic fields of each well. Fluorescence density was quantified using ImageJ software 
(National Institutes of Health, USA).
Annexin A1 blocking
MV were incubated with MaxPab rabbit anti-ANXA1 polyclonal antibody (Abnova, New Taipei, Taiwan) 
at 20 μg/ml for 1 h at 4ºC, then washed with PBS and pelleted at 12.600×g. Chondrocytes were stimulated 
with IL-1β (10 ng/ml) in presence or absence of MV (3.6x107 particles/ml) previously treated with anti-
annexin A1 antibody or MV control for 24 h. IL-6 was determined in supernatants by ELISA and collagen 
type-II in chondrocytes by immunofluorescence as indicated above.
Statistical analysis
Data are expressed as mean and standard error of the mean (mean ± SEM). Data were analyzed by one-
way analysis of variance (ANOVA) followed by the Sidak’s post test using the GraphPad Prism 7.0 software 
(Graph Pad Software, La Jolla, CA, USA). A P value of less than 0.05 was considered statistically significant.
Results
Characterization of EV and effect on cell 
viability
MV and EX fractions were isolated from AD-
MSC CM as indicated in Materials and methods. 
TRPS analysis indicated a mean concentration 
of MV and EX of 8.0x109 and 3.8x1010 particles/
ml, respectively. In addition, we isolated MV 
and EX from HaCaT cells as a negative control 
in functional studies. The MV fraction had an 
average size of 279±94 nm and a concentration 
of 6.5x1010 particles/ml while the EX fraction 
had an average size of 104±19 nm and a 
concentration of 1.1x1012 particles/ml.
Representative TEM images of MV and EX 
from AD-MSC with estimated size are shown 
in Fig. 1A. Immunostaining with gold-labeled 
anti-CD63 antibodies was performed and we 
observed the presence of CD63 labeling in EX 
(Fig. 1B). In addition, 56.7±16.4 % (n=3) of 
annexin V positive MV were detected by flow 
cytometry. To assess the effects of EV on OA 
chondrocytes, we selected the concentrations 
of 3.6x107 particles/ml for MV and 7.2x107 
particles/ml for EX which are in the range of 
concentrations present in CM used in the same 
experiments. We confirmed that MV and EX at 
these concentrations do not affect cell viability 
by the MTT method (Fig. 1C).
Fig. 1. Characterization of MV and EX isolated 
from CM from AD-MSC and effect on cell viabil-
ity. Representative transmission electron mi-
croscopy images of MV and EX with estimated 
size (A). Immunostaining with gold-labeled 
anti-CD63 antibodies (B). Red arrows show 
positive staining. C: Viability (%) of OA chon-
drocytes in the presence of IL-1β and AD-MSC 
EV, determined by the MTT method. Results are 
expressed as mean±SEM from 3 separate exper-
iments with cells from separate donors.
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Effects on cytokines
To study how the production of relevant inflammatory and catabolic mediators was 
modulated by AD-MSC-derived EV, OA chondrocytes were incubated with IL-1β in the 
Fig. 2. Effects of EV and CM from AD-MSC on cytokine release by OA chondrocytes (A) and explants (B). IL-6, 
TNFα and IL-10 were measured by ELISA in culture supernatants. Cultures were treated with IL-1β alone or 
in combination with EV or CM from AD-MSC for 24 h. Results are expressed as mean±SEM from 3 separate 
experiments with cells from separate donors. ++P<0.01 compared to control (non-stimulated cells); *P<0.05, 
**P<0.01 compared to IL-1β; ## P<0.01 compared to CM; &P<0.05 compared to MV.
Fig. 3. Effects of EV and CM from HaCaT cells on cytokine release by OA chondrocytes (A) and explants (B). 
IL-6, TNFα and IL-10 were measured by ELISA in culture supernatants. Cultures were treated with IL-1β 
alone or in combination with EV or CM from HaCaT cells for 24 h. Results are expressed as mean±SEM from 3 
separate experiments with cells from separate donors. ++P<0.01 compared to control (non-stimulated cells).
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presence or absence of MV, EX or CM. 
Stimulation of OA chondrocytes with IL-1β 
for 24 h increased the release of the pro-
inflammatory cytokines IL-6 and TNFα into 
the culture medium compared with control 
non-stimulated cells (Fig. 2A). Treatment 
with MV, EX or CM significantly reduced 
the levels of both pro-inflammatory 
cytokines. In contrast, the release of the 
anti-inflammatory cytokine IL-10 was 
significantly enhanced when cells were 
treated with MV, EX or CM compared with 
cells treated with IL-1β alone. The highest 
effect was exhibited by CM followed by 
MV. In addition, we determined the effects 
of AD-MSC EV on cytokine production 
by OA explants which represent a more 
physiological setting for chondrocytes. As 
shown in Fig. 2B, the behavior of MV, EX and 
CM in OA explants was very similar to that 
observed in OA chondrocytes. In order to 
determine if these effects of MV and EX are 
specific to EV from AD-MSC, we performed 
the same experiments in OA chondrocytes 
and OA explants but using EV and CM 
from HaCaT cells instead of AD-MSC. Fig. 
3A and B shows that MV, EX and CM from 
HaCaT cells were completely ineffective on 
cytokine production by OA chondrocytes or 
explants.
Effects on PGE2 production and COX-2 
and mPGES-1 expression
The levels of PGE
2
 released into the 
culture medium of OA chondrocytes were 
determined to assess if this eicosanoid could 
be regulated by EV. As shown in Fig. 4A, 
PGE
2
 levels in IL-1β-stimulated cells were 
significantly decreased by all treatments. IL-
1β upregulates cyclooxygenase-2 (COX-2) 
and microsomal prostaglandin E synthase-1 (mPGES-1) which act in a coordinated manner 
to synthesize high levels of PGE
2
 during inflammatory responses [25]. We determined the 
mRNA expression of COX-2 (Fig. 4B) and mPGES-1 (Fig. 4C) in OA chondrocytes which was 
reduced by treatment with EV or CM.
Effects on NO production and iNOS expression
IL-1β stimulation of OA chondrocytes results in upregulation of inducible nitric oxide 
synthase (iNOS) and NO production which was estimated by the levels of nitrite present 
in the culture medium (Fig. 5A). We observed that MV, EX and CM significantly decreased 
the levels of nitrite in the medium and the mRNA expression of iNOS in OA chondrocytes 
compared with cells treated with IL-1β alone.
Effects on MMPs
In order to evaluate the effects of treatments on total MMP activity, a fluorometric assay 
was performed as indicated in Materials and methods. Fig. 5B shows that OA chondrocyte 
Fig. 4. PGE
2
 levels and COX-2 and mPGES-1 gene 
expression in OA chondrocytes. A: PGE
2
 levels were 
measured by radioimmunoassay in cell culture su-
pernatants. B: COX-2 and C: mPGES-1 mRNA expres-
sion was determined by real-time PCR as indicated 
in materials and methods. Cultures were treated 
with IL-1β alone or in combination with EV or CM 
from AD-MSC for 24 h (mean±SEM from 5 sepa-
rate experiments with cells from separate donors). ++P<0.01 compared to control (non-stimulated cells); 
*P<0.05, **P<0.01 compared to IL-1β; # P<0.05 com-
pared to CM.
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stimulation with IL-1β resulted in increased MMP 
activity in the culture medium. All treatments 
significantly reduced this activity and MV exerted 
a stronger effect compared with CM. MMP-13 
(collagenase 3) has been implicated in the early 
phase of chondrocyte-mediated cartilage collagen 
breakdown [26]. A consistent induction of MMP-
13 gene expression was seen following IL-1β 
stimulation of OA chondrocytes whereas treatment 
with MV, EX or CM significantly decreased it.
Effects on collagen II expression
It is known that IL-1β suppress the transcription 
of the chondrocyte-specific marker collagen type II 
[4] and induces its degradation [27]. Fig. 6 shows 
that when IL-1β and EV or CM were present in the 
culture medium, these treatments significantly 
relieved the IL-1β-induced suppression of 
chondrocyte-specific collagen type II expression. 
Interestingly, MV were significantly more effective 
than EX or CM leading to a level of collagen II close 
to that of control chondrocytes (non-stimulated 
cells).
Effects on transcription factors
The transcription factor NF-κB mediates many 
of the downstream effects of IL-1β activating the 
transcription of pro-inflammatory and catabolic 
molecules. We have studied the effects of MV, EX and 
CM on the binding of p65 to DNA in the nucleus of 
OA chondrocytes stimulated with IL-1β. There was a 
marked enhancement of p65-DNA binding by this cytokine (Fig. 7A) which was significantly 
reduced by MV, CM and to a lesser extent by EX. AP-1 also plays an important role in MMP 
Fig. 5. NO production and iNOS 
gene expression (A), MMP activity 
and MMP-13 gene expression (B) 
in OA chondrocytes. Nitrite levels 
and MMP activity were measured 
by fluorometry in cell culture su-
pernatants. iNOS and MMP-13 
mRNA expression was determined 
by real-time PCR as indicated in 
materials and methods. Cultures 
were treated with IL-1β alone or in 
combination with EV or CM from 
AD-MSC for 24 h (mean±SEM from 
4 (A) or 3 (B) separate experiments 
with cells from separate donors). 
FU, fluorescence units. ++P<0.01 
compared to control (non-stim-
ulated cells); *P<0.05, **P<0.01 
compared to IL-1β; ## P<0.01 com-
pared to CM.
Fig. 6. Collagen II expression in OA chon-
drocytes. Collagen II protein expression 
was determined by immunofluorescence. 
Cultures were treated with IL-1β alone 
or in combination with EV or CM from 
AD-MSC for 5 days. Results are expressed 
as mean±SEM from 4 separate experi-
ments with cells from separate donors. ++P<0.01 compared to control (non-stimu-
lated cells); **P<0.01 compared to IL-1β; ## P<0.01 compared to CM; &&P<0.01 com-
pared to MV. Bar= 50 µm.
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transcription induced by cytokines [1]. DNA binding of c-Jun AP-1 was significantly activated 
by IL-1β (Fig. 7B) while treatment with MV, EX or CM significantly decreased this process.
Proteomic analysis of AD-MSC EV
We performed a proteomic analysis of AD-MSC EV in order to identify their protein 
content and possible active components. 365 proteins were found in MV preparations, 217 
in EX and 213 in CM. Fig. 8A shows the Venn diagram indicating that 116 proteins were 
identified in MV, EX and CM. MV had a higher number of unshared proteins compared with 
EX (171 vs. 38). These proteins are involved in different cellular process, mainly cellular 
growth and/or maintenance, immune response, protein metabolism and transport (Fig. 8B). 
When compared with CM proteome, 42 unique proteins were identified in MV with a P value 
<0.01. Of them, 15 (Table 1) were over-represented with a fold-change of at least 2.5. Among 
EX proteins, 28 were found significantly different from the CM proteome, but only 3 were 
over-represented with a fold change of at least 2.5.
Fig. 7. Activation of transcription 
factors in OA chondrocytes. P65 NF-
κB (A) and c-jun AP-1 (B) binding 
to DNA was measured by ELISA and 
expressed as arbitrary units (AU) per 
mg of protein. Cultures were treated 
with IL-1β alone or in combination 
with EV or CM from AD-MSC for 1 h. 
Results are expressed as mean±SEM 
from 4 separate experiments with 
cells from separate donors. ++P<0.01 
compared to control (non-stimulated 
cells); *P<0.05, **P<0.01 compared to 
IL-1β; # P<0.05 compared to CM.
Fig. 8. Proteome characterization of EV from AD-MSC. A: Venn 
diagram. The number present in the circle represents the total 
number of identified proteins in particular data sets. B: Most 
over-represented biological processes (gene ontology terms) 
present in EV proteomes.
MV
EX
A B
Protein metabolism
Energy pathways
Metabolism
Transport
Immune response
Cell growth and/or maintenance
Protein metabolism
Cell differentiation
Transport
Immune response
Cell growth and/or maintenance
Intercellular junction assemblyand/or maintenance
Percentage of genes
Percentage of genes
Fig 8
Table 1. Over-represented proteins in AD-MSC EV compared to 
CM Identified protein Uniprot ID Main function MV   Annexin A1 P04083 Immunomodulation Apolipoprotein H P02749 Negtive substrate binding Butyryl-Cholinesterase P06276 Esterase activity CD81 P60033  Endocytic trafficking Dermokine Q6E0U4 Keratinocyte differentiation Fermitin family homolog 3 Q86UX7 Integrin activation 
Integrin β1 P05556  Cell-matrix collagen binding Peroxiredoxin 6 P30041 Peroxidase/Phospholipase A2 Phosphoglycerate mutase 1 P18669 Canonical glycolysis Junction Plakoglobin P14923 α-catenin binding Rab GDP dissociation inhibitor P50395 Rab regulation Tropomyosin 1 P09493  Actin binding Tropomyosin 3  P06753  Actin binding 
α-Actinin 4 O43707 Actin binding 
α-Enolase P06733 Canonical glycolysis EX   Carboxypeptidase N P15169 Inflammatory peptides degradation HSP70 P11142 Molecular chaperone Pregnancy-zone protein F5GXY0 Endopeptidase inhibitor  
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Effects on annexin A1
We have studied CM and EV effects on 
the expression of annexin A1.  This protein 
is over-represented in MV (Table 1) and 
has demonstrated immunomodulatory 
and anti-inflammatory properties in 
different systems (reviewed in [28]). Fig. 
9A shows that annexin A1 expression was 
significantly enhanced by treatment of 
chondrocytes with all fractions and mainly 
with MV. To explore the possibility that 
annexin A1 may contribute to the observed 
anti-inflammatory and chondroprotective 
effects, we neutralized this protein in the 
fraction showing the highest expression 
using a specific antibody and determined 
the consequences on the production of 
the inflammatory cytokine IL-6 and the 
expression of collagen II in OA chondrocytes 
in the presence of IL-1β. Annexin A1 blockade 
significantly reverted the inhibitory effects 
of MV on the inflammatory cytokine IL-6 
(Fig. 9B) and the enhancement of type II 
collagen (Fig. 10).
Discussion
A wide range of evidence indicates 
that paracrine effects of MSC are a central 
mechanism of cell therapy promoting tissue 
regeneration [29, 30]. In line with this view, we have previously shown that CM from AD-
MSC exhibits anti-inflammatory properties in OA chondrocytes [20]. In the present work, we 
Fig. 9. Annexin A1 expression (A) and IL-6 
production after annexin A1 blockade (B) in OA 
chondrocytes. A: Protein expression was determined 
by immunofluorescence. Cultures were treated 
with IL-1β alone or in combination with EV or CM 
from AD-MSC for 24 h. Results are expressed as 
mean±SEM from 4 separate experiments with cells 
from separate donors. FD: fluorescence density. +P<0.05 compared to control (non-stimulated cells); 
**P<0.01 compared to IL-1β. &&P<0.01 compared 
to MV. Bar= 30 µm. B: IL-6 was measured by ELISA 
in cell culture supernatants. Cultures were treated 
with IL-1β alone or in combination with MV from 
AD-MSC after annexin A1 blockade with a specific 
antibody or without blockade. Results are expressed 
as mean±SEM from 3 separate experiments with 
cells from separate donors. ++P<0.01 compared to 
control (non-stimulated cells); **P<0.01 compared 
to IL-1β.
Fig. 10. Collagen II expression after annexin A1 
blockade. Collagen II protein expression was 
determined by immunofluorescence. Cultures were 
treated with IL-1β alone or in combination with 
MV from AD-MSC after annexin A1 blockade with 
a specific antibody or without blockade. Results 
are expressed as mean±SEM from 3 separate 
experiments with cells from separate donors. ++P<0.01 compared to control (non-stimulated cells); 
**P<0.01 compared to IL-1β. Bar= 30 µm.
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have characterized the EV present in this CM and assessed their possible contribution to its 
protective actions.
Synovitis and pro-inflammatory mediators are present in early-stage and late-stage 
OA (reviewed in [31]) and participate in a positive inflammatory feedback loop in the joint 
between synoviocytes and chondrocytes likely involving EV [32]. In OA cartilage, IL-1β and 
TNFα induce a wide range of pro-inflammatory mediators such as cytokines, chemokines, 
PGE
2
, NO and degradative enzymes [31, 33]. Therefore, inflammation is associated to 
progression of cartilage damage in OA and different mediators synergize to amplify and 
perpetuate the process. Our results have shown that MV and EX present in CM from AD-
MSC exert anti-inflammatory effects similar to CM. In contrast, EV from HaCaT cells were 
completely ineffective on cytokine production in OA chondrocytes and explants confirming 
the specificity of the observed effects. The downregulation of the pro-inflammatory cytokines 
TNFα and IL-6 may have implications for the control of altered chondrocyte metabolism. 
Interestingly, IL-6 has been involved in OA pathophysiology [34] and increased circulating 
levels of IL-6 have been associated to radiographic knee OA [35].
MV and EX were also able to counteract the inhibitory effects of IL-1β on the anti-
inflammatory cytokine IL-10. MV treatment determined a significant IL-10 enhancement 
compared with EX, which may be related to its content of annexin A1 [36]. The increased 
production of IL-10 may then contribute to the anti-inflammatory effects of CM and its EV 
as this cytokine inhibits the synthesis of pro-inflammatory cytokines [37] and antagonizes 
their deleterious effects on chondrocyte metabolism [38, 39].
Induction of COX-2 and mPGES-1 and enhanced PGE2 synthesis in articular chondrocytes 
lead to anti-anabolic and degradative effects in the joint [25, 40, 41]. Our results indicate that 
MV and EX are able to control the levels of this eicosanoid through the downregulation of 
COX-2 and mPGES-1. In addition, MV and EX decreased iNOS induction and NO production, 
thus preventing the effects of this mediator on the induction and activation of MMPs and the 
inhibition of extracellular matrix synthesis [42].
The actions of inflammatory mediators in chondrocytes also result in a reduced collagen 
II expression in OA chondrocytes [27]. Our data indicate that EV from AD-MSC protect OA 
chondrocytes from the negative effects of IL-1β on collagen II. These findings suggest a role 
for EV as protective mediators of the differentiated chondrocyte phenotype in inflammatory 
conditions. Components of extracellular matrix and inflammatory mediators stimulate the 
degradation of cartilage by inducing different catabolic enzymes. We have shown that MV 
and to a lesser extent EX, reduced the release of MMP activity. This was accompanied by 
a significant reduction in gene expression of MMP-13 which plays a key role in collagen 
II degradation [43]. Taken as a whole, our results suggest that MV may provide better 
chondroprotection than EX or CM from AD-MSC.
In OA chondrocytes, canonical NF-κB signaling mediates the induction of inflammatory 
mediators and catabolic mechanisms as well as cellular differentiation changes which 
favor the onset and perpetuation of disease [44, 45]. A reduction in the activation of this 
transcription factor by CM and EV could contribute to the observed downregulation of IL-
6, TNFα, COX-2, iNOS and MMPs [46]. There is a significant crosstalk of NF-κB with other 
signaling pathways relevant in OA chondrocytes. In particular, AP-1 cooperates with NF-κB 
in the induction of MMP-13 and other MMPs [1, 47]. Furthermore, IL-1β suppresses collagen 
II expression in articular chondrocytes by inducing the activation of AP-1 and subsequent 
suppression of Sox-9 contributing to the loss of the differentiated chondrocyte phenotype 
[48]. We have shown that MV and EX decrease the DNA binding activities of AP-1 and NF-
κB with an effect of MV similar to CM and higher than EX on the last transcription factor. 
Therefore, the downregulation of MMP activity and MMP-13 gene expression may be the 
consequence of a decreased activation of both transcription factors.
Proteomic analysis indicated the presence of unique proteins in MV and EX fractions of 
AD-MSC CM, and some of them can play a role in the regulation of inflammatory processes and 
immune responses. In particular, annexin A1 is over-represented in MV and exerts complex 
anti-inflammatory and pro-resolution effects. In addition to the inhibition of different 
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inflammatory mediators, annexin A1 exerts suppressive effect on cells of the immune 
system (reviewed in [49]). EV represent a way of cellular communication and transfer of 
components which may be exploited for therapeutic purposes. In this regard, annexin A1 is 
secreted, at least in part, in EV by different cell types such as neutrophils [50] or human bone 
marrow mesenchymal stem cells [51] and it can be delivered into the recipient cell [50, 52]. 
Although further studies are needed to assess the possible contribution of other components 
of AD-MSC EV, our data suggest that annexin A1 may contribute to the anti-inflammatory 
and chondroprotective effects of these microparticles under inflammatory stress conditions. 
These findings are in line with the report that neutrophil MV expressing annexin A1 enhanced 
chondrocyte anabolic properties in vitro, and after in vivo administration to mice protected 
against cartilage degradation in a model of inflammatory arthritis [50].
Conclusion
In summary, we have shown that MV and EX present in the CM of AD-MSC modulate 
chondrocyte metabolism to counteract the effects of IL-1β. Therefore, EV can reproduce 
the anti-inflammatory properties of CM from AD-MSC in OA chondrocytes. Our findings 
are consistent with the hypothesis that EV are mediators of AD-MSC chondroprotective 
actions with a main role for MV. These EV may play important regulatory roles during cell 
communication and represent a novel strategy to develop potential treatments in joint 
conditions.
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